Sarepta Therapeutics Inc [SRPT] stock is trading at $39.54, up 1.72%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SRPT shares have gain 6.20% over the last week, with a monthly amount drifted -37.89%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sarepta Therapeutics Inc [NASDAQ: SRPT] stock has seen the most recent analyst activity on May 08, 2025, when Evercore ISI downgraded its rating to a In-line but kept the price target unchanged to $50 for it. Previously, Wells Fargo started tracking the stock with Overweight rating on April 11, 2025, and set its price target to $115. On April 02, 2025, upgrade upgraded it’s rating to Neutral but maintained its price target of $75 on the stock. RBC Capital Mkts downgraded its rating to a Sector Perform and decreased its price target to $87 on March 31, 2025. Deutsche Bank initiated its recommendation with a Hold and recommended $136 as its price target on February 11, 2025. Needham reiterated a Buy rating for this stock on November 27, 2024, and downed its price target to $202. In a note dated November 25, 2024, H.C. Wainwright initiated an Sell rating and provided a target price of $80 on this stock.
Sarepta Therapeutics Inc [SRPT] stock has fluctuated between $34.10 and $173.25 over the past year. Currently, Wall Street analysts expect the stock to reach $110 within the next 12 months. Sarepta Therapeutics Inc [NASDAQ: SRPT] shares were valued at $39.54 at the most recent close of the market. An investor can expect a potential return of 178.2% based on the average SRPT price forecast.
Analyzing the SRPT fundamentals
Sarepta Therapeutics Inc [NASDAQ:SRPT] reported sales of 2.23B for the trailing twelve months, which represents a growth of 80.15%. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at -0.07%, and Net Profit Margin reading is -0.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.2 and Total Capital is -0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Sarepta Therapeutics Inc’s Current Ratio is 4.02. In addition, the Quick Ratio stands at 2.46 and the Cash Ratio stands at 0.4. Considering the valuation of this stock, the price to sales ratio is 1.74, the price to book ratio is 3.40.
Transactions by insiders
Recent insider trading involved Nicaise Claude, Director, that happened on Mar 12 ’25 when 2491.0 shares were sold. Director, Nicaise Claude completed a deal on Mar 12 ’25 to buy 2491.0 shares. Meanwhile, Director Wigzell Hans Lennart Rudolf sold 10500.0 shares on Dec 12 ’24.
